BOCA RATON, Fla., June 25, 2015 /PRNewswire/ -- Vycor Medical,
Inc. ("Vycor") (OTCQB—VYCO), a provider of innovative and superior
surgical and therapeutic solutions, announced the commercial
release of its Internet-delivered therapy suite in the U.S. This
therapy suite, consisting of its lead Vision Restoration Therapy
(VRT) and its NeuroEyeCoach eye-movement compensation therapy, is
delivered directly to patients over the Internet onto their own
computers replacing the Company's current "prototype hardware
centric" model.
NovaVision has been working to take its VRT therapy prototype
and develop it into an affordable, scalable therapy offering that
offers broader patient benefits. VRT will going forward be provided
alongside NovaVision's NeuroEyeCoach compensatory therapy in one
Internet delivered therapy suite. Two things happen when someone
suffers from vision related disorders following a stroke or brain
injury: there is a loss of visual field as well as difficulty with
eye movement, affecting the ability to integrate visual
information. VRT addresses the restoration of lost vision while
NeuroEyeCoach addresses patients' difficulty with their eye
movements and their ability to integrate visual information,
allowing them to make the most of their remaining vision, The two
therapies provided in a suite are therefore highly complementary
and ensure broad benefits to NovaVision's patients.
NovaVision is now positioned, for the first time, with the suite
of therapies and product offerings to deliver on its strategic
vision: to provide a clinically supported, affordable and scalable
visual therapy solution offering broad benefits to those suffering
visual impairment following neurological damage; and to offer
solutions for both patients and physicians alike.
For Patients:
- VRT and NeuroEyeCoach Therapy Suite. NovaVision
will commercially launch this week these two complementary
therapies, internet-delivered in a package for $900.
- NeuroEyeCoach. For patients with visual
impairments who are not suitable, for whatever reason, for VRT,
NovaVision provides NeuroEyeCoach on its own for $450.
For Physicians:
- Vision Diagnostic (VIDIT). The diagnostic
component of VRT that enables therapists to perform high-resolution
visual field tests in less than 10 minutes to screen for visual
field deficits.
- NeuroEyeCoach Pro Center. Enables stroke
rehabilitation and other centers to treat patients while in their
care, both as in-patient and out-patient.
- NovaVision and NeuroEyeCoach Pro Physician.
Enables physicians to register patients in their clinic who
complete the therapy at home, supported by NovaVision but monitored
by the physician through a dedicated portal.
VRT is a prescription product and the only FDA cleared therapy
(510k) for the restoration of vision loss from neurological damage.
VRT is supported by 15 years of clinical research and over 20
studies including a 302 patient study in which notable improvements
were seen in 70% of the patients. NeuroEyeCoach is also clinically
supported being based on research that has been the subject of 14
clinical studies on a total of 591 patients and has FDA
registration.
Commenting on the Company's announcement, Peter Zachariou, CEO of Vycor, stated: "This has
been a long time coming and has entailed an enormous amount of work
from both our employees but also our scientific advisors and is a
key milestone for NovaVision. We are now finally in a position to
deliver our therapies to the large numbers of people who suffer
vision loss as a result of neurological brain damage as a cost
effective and complete therapy solution. I am convinced that this
new therapy suite is the most robust, affordable and complete
commercially available visual therapy solution targeted at this
type of vision loss. This also represents the final step in moving
NovaVision from being a development company to one focused on
commercializing its unique suite of products. I would urge anyone
who has had a stroke or brain injury and suffers from a visual
disorder to contact us, we have numerous testimonials of patients
for whom these therapies have literally changed their lives".
There are approximately 8m stroke survivors in the U.S. with
795,000 strokes a year, and approximately 1.5m suffering some sort
of Traumatic Brain Injury (TBI) annually; up to 30% of these suffer
a resultant visual impairment, up to 20% permanently. In all,
around 2.8 million Americans suffer from this type of vision
impairment, which is largely unaddressed by the rehabilitation
system. The impact on their daily lives is dramatic, and is the
difference between a person being able to be home alone, cross the
road unaided, drive, shop or read. The new therapy suite is
targeted at this largely underserved group of people.
For an overview of NovaVision see NovaVision Video.
About Vycor Medical, Inc.
With corporate headquarters in Boca
Raton, FL, Vycor Medical, Inc. ("Vycor") is a publicly
traded company (OTCQB—VYCO) dedicated to providing the medical
community with innovative and superior surgical and therapeutic
solutions and has a growing portfolio of FDA cleared medical
solutions that are changing and improving lives every day. The
Company operates two business units: Vycor Medical and NovaVision,
both of which adopt a minimally or non-invasive approach. Both
technologies have exceptional sales growth potential, address large
potential markets, have the requisite regulatory approvals and are
commercialized and generating revenue.
Vycor Medical's ViewSite™ Surgical Access Systems (VBAS) is a
suite of clear cylindrical minimally invasive disposable devices
that hold the potential for speedier, safer and more economical
brain surgeries and a quicker patient discharge. VBAS is
designed to optimize neurosurgical site access, reduce patient
risk, accelerate recovery and add tangible value to the
professional medical community. The company is ISO 13485:2003
compliant, has U.S. FDA 510(k) clearance for brain and spine
surgeries and full regulatory approvals for brain in Australia, Brazil, Canada, China, Europe
(EU – Class III), Korea and Japan
and is seeking or has partial regulatory approvals in India, Russia, Taiwan and Vietnam. For an overview of Vycor Medical's
VBAS see VBAS Video.
NovaVision develops and provides science-driven neurostimulation
therapy and other medical technologies that help improve and
partially restore sight in patients with neurological vision
impairments. The company's proprietary Visual Restoration
Therapy® (VRT) platform is clinically supported to improve lost
vision resulting from stroke, traumatic brain injury ("TBI"), or
other acquired brain injuries. VRT is the only FDA 510K cleared
medical device in the U.S. aimed at the restoration of vision for
neurologically induced vision loss and can be prescribed by any
Physician. VRT also has CE Marking for the EU. NovaVision
also provides Neuro Eye Therapy (NeET) in the EU, aimed at
increasing visual sensitivity deep within the field defect.
The Company has also developed a therapy called NeuroEyeCoach,
which is highly complementary to VRT. The two therapies address
different visual disabilities each of which results from
neurologically-induced vision loss – a loss of visual field as well
as difficulty with eye movement, affecting the ability to integrate
visual information. VRT provides partial restoration of the
patient's lost visual field; NeuroEyeCoach™ is designed to increase
the efficiency of eye movement and re-train the patients' ability
to integrate visual information between the left and right hand
side. For an overview of NovaVision see NovaVision Video.
For the latest information on the company, including media and
other coverage, and to learn more, please go online at
www.vycormedical.com, www.vycorvbas.com or www.novavision.com.
Vycor Medical, Inc Contacts:
6401 Congress Avenue
Suite 140
Boca Raton, FL. 33487
+1-561-558-2020
info@vycormedical.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/vycor-announces-commercial-release-of-its-novavision-web-deliverable-therapy-suite-300104783.html
SOURCE Vycor Medical, Inc.
